150 related articles for article (PubMed ID: 25489765)
1. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
2. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
3. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
4. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Bergamo A; Messori L; Piccioli F; Cocchietto M; Sava G
Invest New Drugs; 2003 Nov; 21(4):401-11. PubMed ID: 14586207
[TBL] [Abstract][Full Text] [Related]
5. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
Messori L; Orioli P; Vullo D; Alessio E; Iengo E
Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
[TBL] [Abstract][Full Text] [Related]
6. Quantum Chemical Studies on Detail Mechanism of Nitrosylation of NAMI-A-HSA Adduct.
Das D; Mondal P
J Phys Chem B; 2015 Aug; 119(33):10456-65. PubMed ID: 26151453
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
8. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
9. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
11. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
12. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
13. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
14. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.
Brindell M; Stawoska I; Supel J; Skoczowski A; Stochel G; van Eldik R
J Biol Inorg Chem; 2008 Aug; 13(6):909-18. PubMed ID: 18438690
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
16. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
[TBL] [Abstract][Full Text] [Related]
17. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
[TBL] [Abstract][Full Text] [Related]
18. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
19. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
20. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
